These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26041577)

  • 1. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
    Pesce E; Bellotti M; Liessi N; Guariento S; Damonte G; Cichero E; Galatini A; Salis A; Gianotti A; Pedemonte N; Zegarra-Moran O; Fossa P; Galietta LJ; Millo E
    Eur J Med Chem; 2015 Jun; 99():14-35. PubMed ID: 26041577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Structure-activity Relationship of Aminoarylthiazole Derivatives as Potential Potentiators of the Chloride Transport Defect in Cystic Fibrosis.
    Liessi N; Pesce E; Salis A; Damonte G; Tasso B; Cichero E; Pedemonte N; Millo E
    Med Chem; 2021; 17(6):646-657. PubMed ID: 32141420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations.
    Pedemonte N; Tomati V; Sondo E; Caci E; Millo E; Armirotti A; Damonte G; Zegarra-Moran O; Galietta LJ
    J Biol Chem; 2011 Apr; 286(17):15215-26. PubMed ID: 21383017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools.
    Liessi N; Cichero E; Pesce E; Arkel M; Salis A; Tomati V; Paccagnella M; Damonte G; Tasso B; Galietta LJV; Pedemonte N; Fossa P; Millo E
    Eur J Med Chem; 2018 Jan; 144():179-200. PubMed ID: 29272749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
    Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.
    Parodi A; Righetti G; Pesce E; Salis A; Tasso B; Urbinati C; Tomati V; Damonte G; Rusnati M; Pedemonte N; Cichero E; Millo E
    Eur J Med Chem; 2020 Dec; 208():112833. PubMed ID: 32971410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.
    Barreca M; Renda M; Spanò V; Montalbano A; Raimondi MV; Giuffrida S; Bivacqua R; Bandiera T; Galietta LJV; Barraja P
    Eur J Med Chem; 2024 Oct; 276():116691. PubMed ID: 39089001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors.
    Righetti G; Casale M; Liessi N; Tasso B; Salis A; Tonelli M; Millo E; Pedemonte N; Fossa P; Cichero E
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
    Cai ZW; Liu J; Li HY; Sheppard DN
    Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview on chemical structures as ΔF508-CFTR correctors.
    Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
    Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating.
    Pedemonte N; Sonawane ND; Taddei A; Hu J; Zegarra-Moran O; Suen YF; Robins LI; Dicus CW; Willenbring D; Nantz MH; Kurth MJ; Galietta LJ; Verkman AS
    Mol Pharmacol; 2005 May; 67(5):1797-807. PubMed ID: 15722457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
    Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
    Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel natural product compound enhances cAMP-regulated chloride conductance of cells expressing CFTR[delta]F508.
    deCarvalho AC; Ndi CP; Tsopmo A; Tane P; Ayafor J; Connolly JD; Teem JL
    Mol Med; 2002 Feb; 8(2):75-87. PubMed ID: 12080183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.
    Sondo E; Tomati V; Caci E; Esposito AI; Pfeffer U; Pedemonte N; Galietta LJ
    Am J Physiol Cell Physiol; 2011 Oct; 301(4):C872-85. PubMed ID: 21753184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
    Veit G; Avramescu RG; Perdomo D; Phuan PW; Bagdany M; Apaja PM; Borot F; Szollosi D; Wu YS; Finkbeiner WE; Hegedus T; Verkman AS; Lukacs GL
    Sci Transl Med; 2014 Jul; 6(246):246ra97. PubMed ID: 25101887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.